Does Rallies show Form 4 insider transactions for CSTL?

Yes. Rallies tracks CSTL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CSTL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CSTL. It does not provide personalized investment advice.

CSTL (Castle Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Castle Biosciences, Inc. Common Stock (CSTL) is a publicly traded Healthcare sector company. As of May 21, 2026, CSTL trades at $20.00 with a market cap of $585.97M and a P/E ratio of -23.44. CSTL moved +4.35% today. Year to date, CSTL is -48.64%; over the trailing twelve months it is +21.39%. Its 52-week range spans $14.59 to $44.28. Analyst consensus is strong buy with an average price target of $44.40. Rallies surfaces CSTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CSTL stock inside the company?

Recent CSTL insider activity includes MAETZOLD DEREK J sold 5.31K, MAETZOLD DEREK J sold 1.16K, MAETZOLD DEREK J sold 985, MAETZOLD DEREK J sold 237, and MAETZOLD DEREK J sold 237. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CSTL Key Metrics

Key financial metrics for CSTL
Metric	Value
Price	$20.00
Market Cap	$585.97M
P/E Ratio	-23.44
EPS	$-0.83
Dividend Yield	0.00%
52-Week High	$44.28
52-Week Low	$14.59
Volume	0
Avg Volume	0
Revenue (TTM)	$344.23M
Net Income	$-24.16M
Gross Margin	79.37%

Recent CSTL Insider Trades

MAETZOLD DEREK J sold 5.31K (~$117.20K) on May 7, 2026.
MAETZOLD DEREK J sold 1.16K (~$25.59K) on May 7, 2026.
MAETZOLD DEREK J sold 985 (~$21.75K) on May 7, 2026.
MAETZOLD DEREK J sold 237 (~$5.23K) on May 7, 2026.
MAETZOLD DEREK J sold 237 (~$5.23K) on May 7, 2026.

Latest CSTL News

Castle Biosciences Wins 2026 Genomics Innovation Award for AdvanceAD-Tx Test — May 12, 2026
Castle Biosciences Q1 Revenue $83.7M; Core Test Reports Up 36% — May 6, 2026
Castle Biosciences' TissueCypher Alters Surveillance in 55% of Barrett's Patients — May 4, 2026
Castle Biosciences Shows 5-Year Risk Prediction Improvement in 1,817 Melanoma Patients — Apr 21, 2026
Castle Biosciences Wins Fifth Consecutive USA TODAY Top Workplaces Award — Apr 10, 2026

CSTL Analyst Consensus

5 analysts cover CSTL: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.40.

Common questions about CSTL

Who is trading CSTL stock inside the company?: Recent CSTL insider activity includes MAETZOLD DEREK J sold 5.31K, MAETZOLD DEREK J sold 1.16K, MAETZOLD DEREK J sold 985, MAETZOLD DEREK J sold 237, and MAETZOLD DEREK J sold 237. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CSTL?: Yes. Rallies tracks CSTL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CSTL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CSTL. It does not provide personalized investment advice.